黑色素瘤免疫治疗早期代谢进展的18F-FDG PET/CT评估
该研究纳入31例接受免疫检查点抑制剂(ICI)治疗的黑色素瘤患者,均在2周期后按EORTC标准判为未确认的进展(uPMD),继续随访PET/CT以确认进展或假性进展。中位随访69.7个月,26/31例最终确认进展,5/31例为假性进展;确认进展者中位OS为10.9个月,假性进展者未达中位OS。应用PERCIMT后假性进展组2/5例被正确判为非进展。确认进展者SLRmean显著高于假性进展者(p=0.038)。
要点
- ICI治疗2周期后PET/CT可识别多数黑色素瘤无应答者。
- EORTC判为uPMD者中83.9%最终确认进展,16.1%为假性进展。
- 确认进展者SLRmean显著高于假性进展者(p=0.038)。
核心结论
- ICI治疗2周期后行18F-FDG PET/CT可识别黑色素瘤免疫治疗中的大多数无应答者。
- 为应对假性进展,建议再次随访PET/CT、采用新型疗效标准并警惕放射性irAE。
- 脾脏葡萄糖代谢(SLR)可能提供额外预后信息。
研究设计与样本
- 纳入31例接受ICI治疗并系列监测18F-FDG PET/CT的黑色素瘤患者。
- 所有患者2周期ICI后按EORTC标准判为uPMD,并至少再随访一次PET/CT以确认cPMD或显示假性进展缓解。
- 同时采用PERCIMT评估,并测量脾/肝18F-FDG摄取比(SLRmean、SLRmax)以探讨免疫激活。
主要发现
- 中位随访69.7个月[64.6-NA]。
- 按EORTC,26/31例uPMD最终为cPMD(83.9%),5/31例为假性进展(16.1%)。
- cPMD组(n=26)中位OS为10.9个月[8.5-NA],假性进展组(n=5)未达中位OS[40.9-NA]。
- 应用PERCIMT后,假性进展组2/5例被正确判为非进展,uPMD队列降至29例,最终26/29例为cPMD(89.7%)、3/29例为假性进展(10.3%)。
- 1例假性进展患者出现短暂性类肉瘤样纵隔/肺门淋巴结病(已知irAE);cPMD者2周期ICI后SLRmean显著高于假性进展者(p=0.038)。
关键数值与推荐
- EORTC标准:2周期ICI后判为PMD者定义为uPMD。
- PERCIMT用于免疫治疗疗效评估,可使部分假性进展者被判为非进展。
- SLRmean在cPMD与假性进展者间差异有统计学意义(p=0.038)。
临床怎么用
- 对ICI治疗2周期后EORTC判为进展的黑色素瘤患者,应再行PET/CT确认,避免将假性进展误判为真进展。
- 可结合PERCIMT等新型免疫治疗疗效标准及对放射性irAE的警惕来提高判读准确性。
- 脾脏18F-FDG摄取比(SLR)可作为潜在预后参考指标。
局限性
- 样本量较小(31例),假性进展组仅5例。
- 为单中心系列观察,未设独立验证队列。
- SLR与预后关系的证据为探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The usage of immune checkpoint inhibitors (ICIs) is the standard practice for the treatment of metastatic melanoma. However, a significant amount of patients show no response to immunotherapy, while issues on its reliable response interpretation exist. Aim of this study was to investigate the phenomenon of early disease progression in 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in melanoma patients treated with ICIs. METHODS: Thirty-one patients under ICIs serially monitored with 18F-FDG PET/CT were enrolled. All patients exhibited progressive metabolic disease (PMD) after two ICIs' cycles according to the European Organization for Research and Treatment of Cancer (EORTC) criteria, and were characterized as unconfirmed PMD (uPMD). They were further followed with at least one PET/CT for either confirmation of PMD (cPMD) or demonstration of pseudoprogression remission. Patients were also evaluated with the PET Response Evaluation Criteria for Immunotherapy (PERCIMT). Moreover, in an attempt to investigate immune activation, the spleen to liver ratios (SLRmean, SLRmax) of 18F-FDG uptake were measured. RESULTS: Median follow up was 69.7 months [64.6-NA]. According to EORTC, 26/31 patients with uPMD eventually showed cPMD (83.9%) and 5/31 patients showed pseudoprogression (16.1%). Patients with cPMD (n = 26) had a median OS of 10.9 months [8.5-NA], while those with pseudoprogression (n = 5) did not reach a median OS [40.9-NA]. Respectively, after application of PERCIMT, 2/5 patients of the pseudoprogression group were correctly classified as non-PMD, reducing the uPMD cohort to 29 patients; eventually, 26/29 patients demonstrated cPMD (89.7%) and 3/29 pseudoprogression (10.3%). One further patient with pseudoprogression exhibited transient, sarcoid-like, mediastinal/hilar lymphadenopathy, a known immune-related adverse event (irAE). Finally, patients eventually showing cPMD exhibited a significantly higher SLRmean than those showing pseudoprogression after two ICIs' cycles (p = 0.038). CONCLUSION: PET/CT, performed already after administration of two ICIs' cycles, can identify the majority of non-responders in melanoma immunotherapy. In order to tackle however, the non-negligible phenomenon of pseudoprogression, another follow-up PET/CT, the usage of novel response criteria and vigilance over emergence of radiological irAEs are recommended. Moreover, the investigation of spleen glucose metabolism may offer further prognostic information in melanoma patients under ICIs.
引用
- Sachpekidis C, Kopp-Schneider A, Hassel JC, et al. Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study. EJNMMI Res. 2021. PMID: 34495433. doi:10.1186/s13550-021-00832-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。